You are here

Article Text

Article menu

Download PDFPDF

Review
The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis
Free
  1. Sonia Abilleira,
  2. Steve Bevan,
  3. Hugh S Markus
  1. Department of Clinical Neuroscience, St George’s University of London, London, UK
  1. Correspondence to:
 S Abilleira
 Agència d’Avaluació de Tecnologia i Recerca Mèdiques (AATRM), Parc Sanitari Pere Virgili, C/Esteve Terrades 30, Edifici Tramuntana, 2a planta, Barcelona 08023, Spain; sabilleira{at}aatrm.catsalut.net

Abstract

Current evidence suggests that matrix metalloproteinases (MMPs) have a role in early atherosclerosis, plaque rupture and myocardial infarction. Polymorphisms in MMP genes have been examined for associations with atherosclerosis, but interpretation is complicated by methodological issues. This article presents a systematic review of these association studies and a meta-analysis of available data for polymorphisms where a sufficient number of studies was available. The 5A allele of the MMP3 5A/6A polymorphism was associated with acute myocardial infarction (odds ratio (OR) 1.26, 95% confidence interval (CI) 1.1 to 1.4, p<0.001), suggesting its role in plaque rupture. There was no association with the functional MMP9 −1562C/T polymorphism (OR 1.11, 95% CI 1.0 to 1.3, p = 0.18). Current data provide evidence for the role of MMP3 polymorphism in plaque destabilisation, but elucidation of the role of other MMP gene variants in atherosclerosis will depend on better study design, including a larger sample size, extensive screening of individual genes with haplotype analysis and replication of studies to avoid publication bias.

  • CAD, coronary artery disease
  • IMT, intima–media thickness
  • MMP, matrix metalloproteinase

https://doi.org/10.1136/jmg.2006.040808

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Atherosclerosis is the major cause of coronary artery disease (CAD) and stroke. Although much of the risk for this condition is explained by conventional risk factors, a great deal remains unexplained. Gene–environment interactions may be particularly relevant. Most studies have looked at associations between polymorphic variants in candidate genes and atherosclerosis, quantified by imaging or cardiovascular end points. A potential candidate gene system is the matrix metalloproteinase (MMP) family.

    The MMPs are proteolytic enzymes that degrade the extracellular matrix, leading to connective tissue remodelling during normal biological processes. Vascular remodelling is currently recognised as a determinant of major vascular pathologies including atherosclerosis and restenosis,1 and it is now widely accepted that deregulation of the MMP system has a pivotal role in vascular remodelling and atherosclerosis (table 1).2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28

    View this table:
    Table 1

     Roles of matrix metalloproteinases in atherosclerosis

    Studying genetic variants in the MMPs, which are associated with lifelong changes in MMP activity, offers the possibility of determining whether such relationships are really causal. Using genetic variants in this way is referred to as “mendelian randomisation”, and has recently been used to determine causality in cardiovascular and other complex diseases.29

    In this article, we present a critical examination of the association between MMP polymorphisms and atherosclerosis, focusing on coronary and carotid atherosclerosis.

    Search strategy

    We performed a computer-based search using the PubMed database with the following search terms: “matrix metalloproteinases” and “atherosclerosis”, “coronary artery disease”, “carotid stenosis”, “intima-media thickness”, “polymorphism” and “genetics”. References from the retrieved articles were also screened for additional papers. Publications in English until November 2005 were included. Papers on aneurysms were not reviewed.

    We reviewed all association studies on polymorphic variants in the MMP genes in patient groups with subclinical atherosclerosis or clinical coronary or carotid atherosclerosis. For each study, several markers of quality were determined, including details of clinical phenotyping, degree of controlling for ethnicity and other cardiovascular risk factors. Where data from ⩾3 similar studies were available, meta-analysis was performed using the Mantel–Haenszel method. This was possible for case–control studies of the MMP3 5A/6A and MMP9 −1562C/T polymorphisms. As MMPs may have different roles in early atherosclerosis and in late disease, we analysed studies with the end point of atherosclerotic stenosis on imaging separately from those with the end point of acute symptomatic events (myocardial infarction).

    POLYMORPHISMS OF MMPS TESTED FOR ASSOCIATIONS WITH CORONARY AND CAROTID ATHEROSCLEROSIS

    Genetic association studies with cardiovascular disease have used a range of phenotypes. Clinical end points such as myocardial infarction, angina or stroke, and intermediate phenotypes of subclinical atherosclerosis can both be used. The intermediate phenotypes have been measured using high-resolution duplex ultrasound of the carotid arteries or angiographic imaging of the coronary arteries. The use of intermediate phenotypes is statistically more powerful because continuous variables are used, and because the phenotypes overcome the problem of subclinical disease, in which a control, in a case–control study, may have presymptomatic atherosclerosis. It is important to remember that intermediate phenotypes deal with only part of the pathogenic process, and therefore associations may occur with clinical events but not with intermediate phenotypes. For example, a gene associated with plaque rupture leading to myocardial infarction may not be associated with early arteriosclerosis detected on carotid ultrasound. A popular intermediate phenotype is intima–media thickness (IMT) and carotid plaque on carotid ultrasound, which is non-invasive and can be applied in large population studies. Numerous studies have shown that IMT is an independent predictor of risk for myocardial infarction and stroke,30–33 and seems to represent early arteriosclerosis.34 However, it may also represent remodelling changes in response to vascular risk factors such as hypertension.

    The MMP3 5A/6A polymorphism

    Coronary artery disease

    An association between the MMP3 5A/6A promoter polymorphism and atherosclerosis was first described in 1995: the 6A6A genotype was associated with greater progression of coronary atherosclerosis.35 Functional studies showed that the 6A allele was associated with twofold lower transcriptional activity.36

    Several investigators have used the clinical end point of coronary atherosclerosis or its progression, and >6000 people have been included in such analyses. The 6A6A genotype was associated with a greater progression of CAD after angioplasty.37 In a prospective drug trial comparing gemfibrozil with placebo in 371 patients with prior coronary artery bypass graft, the 6A allele was associated with atheroma progression during the 32-month follow-up in placebo-treated patients, whereas in the gemfibrozil arm, changes were less marked.38 In 1240 Caucasians, the number of coronary arteries with >50% stenosis increased with increasing frequency of the 6A6A genotype, whereas the 5A5A genotype increased the risk of myocardial infarction among those with at least one artery with >50% stenosis.39 In 1011 Japanese people with CAD, the 6A allele was an independent risk factor for CAD in women without cardiovascular risk factors.40 However, not all studies have found the 6A allele to be associated with CAD. A small study on 131 Koreans with CAD and 117 controls found an association between the 5A allele and stable angina.41 In 3333 patients with CAD treated with either percutaneous coronary interventions or stent, no association was reported with angiographic restenosis,42 consistent with the results of a case–control study of 204 Caucasians with CAD and 267 controls.43

    Other studies have used the end point of myocardial infarction; here an association could represent a role in atherosclerosis, or plaque instability and rupture. The high-activity 5A allele is suggested to predispose a patient to plaque rupture, a hypothesis supported by positive associations reported with acute myocardial infarction in young (<45 years) Han-Chinese patients from Taiwan,44 Han-Chinese patients from China45 and two separate Japanese cohorts.46,47 By contrast, a genomewide association study looking at 112 polymorphisms in 71 candidate genes in 4152 Japanese people found an association between the 6A allele and myocardial infarction, although this was confined to women.48 Similarly, a recent study showed that serum concentration of MMP3 is influenced by the MMP3 genotype and associated with myocardial infarction, although this association was seen between myocardial infarction and the 6A allele, particularly among men.49 A possible interaction between the 5A allele and smoking was reported in a Taiwanese population with acute myocardial infarction,44 and a similar interaction was reported in a cohort study of 2743 British middle-aged men.50 Of the 125 who developed acute coronary events, 6A6A carriers had a higher relative risk of acute CAD events among non-smokers, whereas among smokers an association was found with the 5A5A genotype. A possible interaction has also been reported with the pleiotropic effects of pravastatin in the Regression Growth Evaluation Statin Study trial.51 Treatment with pravastatin reduced the clinical event rate and the need for repeated angioplasties in those with the 6A allele. This effect was independent of the lipid-lowering effects of pravastatin.

    The 5A allele was associated with calcified coronary lesions in an autopsy series of Finnish men, although no association was found with complicated lesions or myocardial infarction.52 In a recent publication using the same autopsy series, this group showed that the combined MMP3 5A/6A and MMP9 −1652C/T genotype status represented a major risk factor for coronary complicated plaques, with the combination of both high-activity alleles showing a considerable association with the area of the complicated plaque.53 The MMP3 polymorphism has also been explored in relation to aortic stiffening. The 5A and 6A homozygotes aged >60 years had greater aortic stiffness, whereas heterozygotes showed more elastic aortas and a level of gene and protein expression intermediate between the two homozygotes.54 Finally, the 5A allele was associated with coronary aneurysms in patients with CAD,26 suggesting that a proteolytic balance in favour of extracellular matrix destruction may underlie the pathological occurrence of aneurysms.

    Carotid atherosclerosis

    Four studies have examined the role of the 5A/6A polymorphism in carotid atherosclerosis, and all have shown association with the 6A allele. Three of them studied associations with IMT and one with degree of carotid stenosis. In healthy Caucasian men without major risk factors for atherosclerosis, the 6A allele was associated with increased carotid IMT, enlarged arterial lumen and a local reduction in wall shear stress.55 This association was confirmed in a further study on healthy men, and additive effects were found with the interleukin 6 (−174G/C) promoter polymorphism.56 Similar associations were found in 87 Hispanic people from the Northern Manhattan Prospective Cohort Study, who had had no stroke,57 and with degree of carotid stenosis in an Italian study.58 The combination of the MMP3 6A6A genotype and the MMP1 2G2G genotype (MMP1 −1607 1G/2G polymorphism) was an independent risk factor for internal carotid artery stenosis.58

    In summary, some studies have shown associations between the low-activity 6A allele and both coronary and carotid atherosclerosis and increased IMT. This suggests that people with the 6A6A genotype, who produce less MMP3, show a change in matrix turnover, favouring deposition of matrix and accelerated atherosclerosis. By contrast, several studies have shown an association between the high-activity 5A allele and acute coronary events, suggesting its role in plaque rupture due to increased proteolysis. We pooled together data from seven studies that had looked at associations with myocardial infarction.39,44–49 The meta-analysis showed a moderate genetic influence of the 5A allele as a plaque-disrupting risk factor (odds ratio (OR) 1.26, 95% confidence interval (CI) 1.1 to 1.4, p<0.001; fig 1). However, heterogeneity was highly significant across studies (p<0.001). Heterogeneity is possibly suggested by the study of Yamada et al,48 where a large group of Japanese patients with myocardial infarction was investigated. In this study, an association was seen between the 6A allele and myocardial infarction only in women. Patients in Yamada et al’s study were older than those in the other studies. A possible explanation for the heterogeneity might be that in older women, myocardial infarction develops from severe flow-limiting stenoses rather than from complicated lesions.

    Figure 1
    Figure 1

     Odds, for patients with myocardial infarction (MI) versus controls, of carrying the 5A allele (matrix metalloproteinase 3 5A/6A polymorphism). x axis: odds ratio (OR) and 95% CI; y axis: studies included in the meta-analysis.

    Other MMP3 polymorphisms

    Beyzade et al39 genotyped 1240 Caucasians for six MMP3 polymorphisms (−1986T/C, −1612 5A/6A, −1346A/C, −709A/C, −376G/C and +802A/G) and found none of them, except 5A/6A, significantly associated with CAD (p<0.05). A recent case–control study on three MMP3 polymorphisms (5A/6A, −376C/G and the coding Gly45Lys) through haplotype analysis showed an association between the 5A–G–Lys haplotype and an increased risk of myocardial infarction, although the effect of the haplotype was mainly due to the 5A/6A polymorphism.45

    MMP9 polymorphisms

    Zhang et al59 described a functional −1562C/T polymorphism in the promoter region of MMP9. Transfection experiments and DNA–protein interaction assays indicated that the T allele had higher activity; an association with severity of coronary atherosclerosis measured by the number of coronary arteries showing >50% stenosis was reported, although no association was seen with myocardial infarction. Others have confirmed this association with CAD.60,61 The T allele has also been associated with complicated coronary lesions,62 and carriers of the T allele had greater levels of MMP9 mRNA and protein, and stiffer large arteries.63 In a prospective study,64 the T allele was associated with raised plasma MMP9 levels, which themselves predicted cardiovascular mortality in patients with CAD, although the T allele itself was not associated with mortality. Three published studies on 788 Caucasians, 248 Koreans and 2731 German men with angiographically documented CAD failed to confirm an association with the T allele.41,65,66 We carried out a meta-analysis of five studies41,60,61,65,66 and found no association between the T allele and angiographically documented coronary atherosclerosis (OR 1.11, 95% CI 1.0 to 1.3, p = 0.18; fig 2).

    Figure 2
    Figure 2

     Odds of carrying the T allele (matrix metalloproteinase MMP9 –1562C/T polymorphism) for angiographically documented patients with coronary artery disease (CAD). x axis: odds ratio (OR) and 95% CI; y axis: studies included in the meta-analysis.

    Three more MMP9 polymorphisms have been studied: a CA repeat, +6C/T and the coding R279Q. In one study, the 279Q allele was associated with increased MMP9 levels and the combined end point of cardiovascular death and non-fatal myocardial infarction,64 whereas in another, neither R279Q nor +6C/T was associated with CAD.60 The CA repeat and the R279Q polymorphisms were not associated with coronary aneurysms and stable angina in two other studies.26,41

    Other MMP polymorphisms

    Ye et al43 showed a reduced risk of CAD in 471 Caucasians with the MMP1 2G2G genotype (MMP1 −1607 1G/2G polymorphism). However, in a study on 164 patients with myocardial infarction and 335 controls, no association was seen with this polymorphism.47 In another study, no significant associations of MMP2 −1306C/T and MMP12 −82A/G were reported with aneurysmal CAD.26 A case–control study on patients with triple-vessel CAD looked at four MMP2 promoter polymorphisms (−1575G/A, −1306C/T, −790T/G and −735C/T), and showed a twofold higher risk of triple-vessel disease for the MMP2 –790T allele.67 Two common functional polymorphisms have been identified in the promoter region of the MMP7 gene,68 and both were associated with smaller luminal diameters but only among people with hypercholesterolaemia, suggesting either an allele-specific effect of cholesterol on MMP7 expression or MMP7 expression only under hypercholesterolaemic conditions. The MMP12 −82A/G polymorphism was also studied in 367 patients with established CAD, and the G allele, which shows lower transcriptional activity in vitro, was associated with a greater luminal diameter in patients with diabetes undergoing angioplasty with stent implantation.69 Finally, no linkage was reported between loci of tissue inhibitor of metalloproteinases 1, 2 and 3 and premature CAD.70

    CONCLUSIONS

    Considerable evidence, including data from genetically engineered mice, expression studies on atherosclerotic tissue and measurement of circulating markers, has implied a role of MMPs in atherosclerosis. Evidence from expression studies and circulating markers cannot prove causality, because changes could be secondary to the disease process itself rather than having a causal role. The study of polymorphisms, which are associated with changes in MMP activity, are present since birth and therefore give an estimate of lifelong exposure, enables further information on causality to be obtained. Several genetic association studies with MMP variants have been performed, although conclusions from many of these are complicated by poor methodology, particularly small sample sizes, and by the possibility of publication bias. The most studied polymorphisms are the MMP3 5A/6A and the MMP9 −1562C/T. The MMP3 6A6A genotype is suggested to be associated with atherosclerosis, and the 5A allele with plaque rupture. On meta-analysis of published studies, we found a marked association between the 5A allele and acute events (myocardial infarction), suggesting its possible role in plaque rupture. A meta-analysis of studies associating the MMP9 polymorphism with CAD found no evidence of an association. The number of studies examining the association with polymorphisms in other MMP genes is limited, and no meta-analysis of these data was possible.

    In summary, genetic association studies suggest a role of MMP3 in plaque rupture. However, conclusions are limited by poor methodology in many studies. Further progress will depend on improved methods, including larger sample sizes, genotyping of haplotypes rather than single-nucleotide polymorphisms, better matching of cases and controls, controlling for conventional cardiovascular risk factors and, importantly, replicating positive findings in a second independent population before publication.

    Acknowledgments

    We thank Peter Rothwell and Enrico Flossmann for the meta-analysis software.

    REFERENCES

    1. ↵
      Gibbons GH, Dzau VJ. The emerging concept of vascular remodelling. N Engl J Med1994;330:1431–8.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ Res2002;90:251–62.
      OpenUrlAbstract/FREE Full Text
    3. ↵
      Galis Z, Muszynski M, Sukhova GK, Simon-Morrisey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci1995;748:501–7.
      OpenUrlPubMedWeb of Science
    4. ↵
      Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation1999;99:420–6.
    5. ↵
      Zempo N, Kenagy RD, Au YP, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg1994;20:209–17.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation1995;91:2125–31.
    7. ↵
      Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest2000;105:1641–9.
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res1994;75:539–45.
      OpenUrlAbstract/FREE Full Text
    9. ↵
      Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res1996;79:812–20.
      OpenUrlAbstract/FREE Full Text
    10. ↵
      Mason DP, Kenagy RD, Hasenstab D, Bowen-Pope DF, Seifert RA, Coats S, Hawkins SM, Clowes AW. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res1999;85:1179–85.
      OpenUrlAbstract/FREE Full Text
    11. ↵
      Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res1996;78:38–43.
      OpenUrlAbstract/FREE Full Text
    12. ↵
      Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res1994;75:41–54.
      OpenUrlAbstract/FREE Full Text
    13. ↵
      Aguilera CM, George SJ, Johnson JL, Newby AC. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res2003;58:679–88.
      OpenUrlAbstract/FREE Full Text
    14. ↵
      Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol1994;125:1165–78.
      OpenUrlAbstract/FREE Full Text
    15. ↵
      Prescott MF, Sawyer WK, Von Linden-Reed J, Jeune M, Chou M, Caplan SL, Jeng AY. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12 and MMP-13 and on restenosis in rats after balloon injury. Ann N Y Acad Sci1999;878:179–90.
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      Coats WD Jr, Whittaker P, Cheung DT, Curier JW, Han B, Faxon DP. Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation1997;95:1293–300.
    17. ↵
      Pasterkamp G, Schoneveld AH, Hijnen DJ, de Leijn DP, Teepen H, van der Valt AC, Borst C. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis2000;150:245–53.
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke2000;31:40–7.
      OpenUrlAbstract/FREE Full Text
    19. ↵
      Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR, Loftus IM. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation2004;110:337–43.
    20. ↵
      Morgan AR, Rerkasem K, Gallagher PJ, Zhang B, Morris GE, Calder PC, Grimble RF, Eriksson P, McPheat WL, Shearman CP, Ye S. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke2004;35:1310–15.
      OpenUrlAbstract/FREE Full Text
    21. ↵
      Alvarez B, Ruiz C, Chacon P, Alvarez-Sabin J, Matas M. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg2004;40:469–75.
      OpenUrlCrossRefPubMedWeb of Science
    22. ↵
      Bicknell CD, Peck D, Alkhamesi NA, Cowling MG, Clark MW, Goldin R, Foale R, Jenkins MP, Wolfe JH, Darzi AW, Cheshire NJ. Relationship of matrix metalloproteinases and macrophages to embolization during endoluminal carotid interventions. J Endovasc Ther2004;11:483–93.
      OpenUrlCrossRefPubMed
    23. ↵
      Nikkari ST, O’Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation1995;92:1393–8.
    24. ↵
      Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest1994;94:2493–503.
      OpenUrlCrossRefPubMedWeb of Science
    25. ↵
      Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol1998;32:368–72.
      OpenUrlCrossRefPubMedWeb of Science
    26. ↵
      Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol2002;40:43–8.
      OpenUrlCrossRefPubMedWeb of Science
    27. ↵
      Nollendorfs A, Greiner TC, Nagase H, Baxter BT. The expression and localization of membrane type-1 matrix metalloproteinase in human abdominal aortic aneurysms. J Vasc Surg2001;34:316–22.
      OpenUrlCrossRefPubMedWeb of Science
    28. ↵
      Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest2002;110:625–32.
      OpenUrlCrossRefPubMedWeb of Science
    29. ↵
      Davey Smith G, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol2003;32:1–22.
      OpenUrlAbstract/FREE Full Text
    30. ↵
      Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens2002;20:159–69.
      OpenUrlCrossRefPubMedWeb of Science
    31. Kablak-Ziembicka A, Tracz W, Przewlocki T, Pieniazek P, Sokolowski A, Konieczynska M. Association of increased carotid intima-media thickness with the extent of coronary artery disease. Heart2004;90:1286–90.
      OpenUrlAbstract/FREE Full Text
    32. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation2004;109:1089–94.
    33. ↵
      Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med1998;128:262–9.
      OpenUrlCrossRefPubMedWeb of Science
    34. ↵
      de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation2004;109:III33–8.
    35. ↵
      Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J1995;73:209–15.
      OpenUrlAbstract/FREE Full Text
    36. ↵
      Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem1996;271:13055–60.
      OpenUrlAbstract/FREE Full Text
    37. ↵
      Humphries S, Bauters C, Meirhaeghe A, Luong L, Bertrand M, Amouyel P. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J2002;23:721–5.
      OpenUrlAbstract/FREE Full Text
    38. ↵
      Humphries SE, Luong LA, Talmud PJ, Frick MH, Kesaniemi YA, Pasternak A, Taskinen MR, Syvanne M. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Atherosclerosis1998;139:49–56.
      OpenUrlCrossRefPubMedWeb of Science
    39. ↵
      Beyzade S, Zhang S, Wong YK, Day IN, Eriksson P, Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol2003;41:2130–7.
      OpenUrlCrossRefPubMedWeb of Science
    40. ↵
      Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol2003;42:1429–37.
      OpenUrlCrossRefPubMedWeb of Science
    41. ↵
      Kim JS, Park HY, Kwon JH, Im EK, Choi D, Jang Y, Cho SY. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J2002;43:473–81.
      OpenUrlPubMedWeb of Science
    42. ↵
      Hoppmann P, Koch W, Schomig A, Kastrati A. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. Eur Heart J2004;25:335–41.
      OpenUrlAbstract/FREE Full Text
    43. ↵
      Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J2003;24:1668–71.
      OpenUrlAbstract/FREE Full Text
    44. ↵
      Liu PY, Chen JH, Li YH, Wu HL, Shi GY. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost2003;90:132–9.
      OpenUrlPubMedWeb of Science
    45. ↵
      Zhou X, Huang J, Chen J, Su S, Chen R, Gu D. Haplotype analysis of the matrix metalloproteinase-3 gene and myocardial infarction in a Chinese Han population. The Beijing Atherosclerosis Study. Thromb Haemost2004;92:867–73.
      OpenUrlPubMedWeb of Science
    46. ↵
      Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, Matsuda Y, Takai E, Iwai C, Kurogane H, Yoshida Y, Yokoyama M. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation1999;99:2717–19.
    47. ↵
      Nojiri T, Morita H, Imai Y, Maemura K, Ohno M, Ogasawara K, Aizawa T, Saito A, Hayashi D, Hirata Y, Sugiyama T, Yamasaki T, Nagai R. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol2003;92:181–6.
      OpenUrlCrossRefPubMedWeb of Science
    48. ↵
      Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med2002;347:1916–23.
      OpenUrlCrossRefPubMedWeb of Science
    49. ↵
      Samnegard A, Silveira A, Lundman P, Boquist S, Odeberg J, Hulthe J, McPheat W, Tornvall P, Bergstrand L, Ericsson CG, Hamsten A, Eriksson P. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 –1612 5A/6A promoter genotype and associated with myocardial infarction. J Int Med2005;258:411–19.
      OpenUrlCrossRefPubMedWeb of Science
    50. ↵
      Humphries SE, Martin S, Cooper J, Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet2002;66:343–52.
      OpenUrlCrossRefPubMedWeb of Science
    51. ↵
      de Maat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, Kastelein JJ, van Boven AJ, Bruschke AV, Humphries SE, Kluft C, Henney AM. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol1999;83:852–6.
      OpenUrlCrossRefPubMedWeb of Science
    52. ↵
      Pollanen PJ, Lehtimaki T, Ilveskoski E, Mikkelsson J, Kajander OA, Laippala P, Perola M, Goebeler S, Penttila A, Mattila KM, Syrjakoski K, Koivula T, Nikkari ST, Karhunen PJ. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study. Atherosclerosis2002;164:329–35.
      OpenUrlCrossRefPubMedWeb of Science
    53. ↵
      Pollanen PJ, Lehtimaki T, Mikkelsson J, Ilveskoski E, Kunnas T, Perola M, Penttila A, Mattila KM, Nikkari ST, Syrjakoski K, Karhunen PJ. Matrix metalloproteinase 3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis2005;180:73–8.
      OpenUrlCrossRefPubMedWeb of Science
    54. ↵
      Medley TL, Kingwell BA, Gatzka CD, Pillay P, Cole TJ. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and -protein expression. Circ Res2003;92:1254–61.
      OpenUrlAbstract/FREE Full Text
    55. ↵
      Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S, Massoud R, Mattioli PL, Federici G, Cortese C. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol2000;20:1600–5.
      OpenUrlAbstract/FREE Full Text
    56. ↵
      Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, Toyry J, Humphries SE. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol2000;20:2657–62.
      OpenUrlAbstract/FREE Full Text
    57. ↵
      Rundek T, Elkind MS, Pittman J, Boden-Albala B, Martin S, Humphries SE, Juo SH, Sacco RL. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke2002;33:1420–3.
      OpenUrlAbstract/FREE Full Text
    58. ↵
      Ghilardi G, Biondi ML, DeMonti M, Turri O, Guagnellini E, Scorza R. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke2002;33:2408–12.
      OpenUrlAbstract/FREE Full Text
    59. ↵
      Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation1999;99:1788–94.
    60. ↵
      Morgan AR, Zhang B, Tapper W, Collins A, Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med2003;81:321–6.
      OpenUrlPubMedWeb of Science
    61. ↵
      Cho HJ, Chae IH, Park KW, Ju JR, Oh S, Lee MM, Park YB. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet2002;47:88–91.
      OpenUrlCrossRefPubMed
    62. ↵
      Pollanen PJ, Karhunen PJ, Mikkelsson J, Laippala P, Perola M, Penttila A, Mattila KM, Koivula T, Lehtimaki T. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol2001;21:1446–50.
      OpenUrlAbstract/FREE Full Text
    63. ↵
      Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix metallaproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol2004;24:1479–84.
      OpenUrlAbstract/FREE Full Text
    64. ↵
      Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation2003;107:1579–85.
    65. ↵
      Wang J, Warzecha D, Wilcken D, Wang XL. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci (London)2001;101:87–92.
      OpenUrl
    66. ↵
      Haberbosch W, Gardemann A. Gelatinase B (C–1652 T) polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest2005;65:513–22.
      OpenUrlCrossRefPubMed
    67. ↵
      Vasku A, Goldbergova M, Izakovicova Holla L, Siskova L, Groch L, Beranek M, Tschoplova S, Znojil V, Vacha J. A haplotype constituted of four MMP-2 promoter polymorphisms (−1575G/A, −1306C/T, −790T/G and −735C/T) is associated with coronary triple-vessel disease. Matrix Biol2004;22:585–91.
      OpenUrlCrossRefPubMedWeb of Science
    68. ↵
      Jormsjo S, Whatling C, Walter DH, Zeiher AM, Hamsten A, Eriksson P. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol2001;21:1834–9.
      OpenUrlAbstract/FREE Full Text
    69. ↵
      Jormsjo S, Ye S, Moritz J, Walter DH, Dimmeler S, Zeiher AM, Henney A, Hamsten A, Eriksson P. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res2000;86:998–1003.
      OpenUrlAbstract/FREE Full Text
    70. ↵
      Dorsch MF, Barrett JA, Lawrance RA, Maqbool A, Durham NP, Ellis S, Samani NJ, Bishop T, Ball SG, Balmforth AJ, Hall AS. Premature coronary artery disease shows no evidence of linkage to loci encoding for tissue inhibitors of matrix metalloproteinases. J Hum Genet2003;48:508–13.
      OpenUrlCrossRefPubMed

    Footnotes

    • Published Online First 11 August 2006

    • Competing interests: None.